Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ALPACA trial. The 400-mg dose cut Lp(a) by 93.9 percentage points compared ...

RVG–9R might not only be a highly promising drug delivery system for siRNA and potentially other therapeutic molecules, but also a powerful tool to systematically analyse gene function in the ...